167 related articles for article (PubMed ID: 34076400)
41. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.
Leyden JJ; Tanghetti EA; Miller B; Ung M; Berson D; Lee J
Cutis; 2002 Feb; 69(2 Suppl):12-9. PubMed ID: 12095064
[TBL] [Abstract][Full Text] [Related]
42. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
[TBL] [Abstract][Full Text] [Related]
43. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.
Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J
Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
[TBL] [Abstract][Full Text] [Related]
45. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
[TBL] [Abstract][Full Text] [Related]
46. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
Shalita AR; Chalker DK; Griffith RF; Herbert AA; Hickman JG; Maloney JM; Miller BH; Tschen EH; Chandraratna RA; Gibson JR; Lew-Kaya DA; Lue JC; Sefton J
Cutis; 1999 Jun; 63(6):349-54. PubMed ID: 10388959
[TBL] [Abstract][Full Text] [Related]
47. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Sugarman JL; Weiss J; Tanghetti EA; Bagel J; Yamauchi PS; Stein Gold L; Lin T; Martin G; Pillai R; Israel R
J Drugs Dermatol; 2018 Aug; 17(8):855-861. PubMed ID: 30124724
[TBL] [Abstract][Full Text] [Related]
48. Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants.
Cook-Bolden FE; Hebert AA; Guenthner ST; Kang R; Martin G; Jacobson A
J Drugs Dermatol; 2020 Aug; 19(8):747-754. PubMed ID: 32845589
[TBL] [Abstract][Full Text] [Related]
49. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-severe Acne Vulgaris in a Preadolescent and Adolescent Population.
St Surin-Lord S; Schlesinger TE; Guenin E
J Clin Aesthet Dermatol; 2019 Sep; 12(9):E57-E61. PubMed ID: 31641421
[No Abstract] [Full Text] [Related]
50. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.
Hebert A; Thiboutot D; Stein Gold L; Cartwright M; Gerloni M; Fragasso E; Mazzetti A
JAMA Dermatol; 2020 Jun; 156(6):621-630. PubMed ID: 32320027
[TBL] [Abstract][Full Text] [Related]
51. A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne.
Mazzetti A; Moro L; Gerloni M; Cartwright M
J Drugs Dermatol; 2019 Jun; 18(6):570. PubMed ID: 31251550
[TBL] [Abstract][Full Text] [Related]
52. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
Leyden J; Thiboutot DM; Shalita AR; Webster G; Washenik K; Strober BE; Shupack J
Arch Dermatol; 2006 May; 142(5):605-12. PubMed ID: 16702498
[TBL] [Abstract][Full Text] [Related]
53. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris.
Pariser D; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s18-23. PubMed ID: 18575222
[TBL] [Abstract][Full Text] [Related]
54. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
[TBL] [Abstract][Full Text] [Related]
55. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris.
Kakita L
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S51-4. PubMed ID: 10898831
[TBL] [Abstract][Full Text] [Related]
56. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
Tanghetti E; Dhawan S; Torok H; Kircik L
Dermatol Online J; 2007 Jul; 13(3):1. PubMed ID: 18328195
[TBL] [Abstract][Full Text] [Related]
57. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study.
Grimes P; Callender V
Cutis; 2006 Jan; 77(1):45-50. PubMed ID: 16475496
[TBL] [Abstract][Full Text] [Related]
58. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
Leyden JJ
Cutis; 2004 Oct; 74(4 Suppl):9-15. PubMed ID: 15543714
[TBL] [Abstract][Full Text] [Related]
59. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
Stein Gold L; Bagel J; Lebwohl M; Lin T; Martin G; Pillai R
J Drugs Dermatol; 2018 Dec; 17(12):1290-1296. PubMed ID: 30586261
[TBL] [Abstract][Full Text] [Related]
60. Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream.
Draelos Z; Tanghetti E; Guenin E
J Drugs Dermatol; 2022 Aug; 21(8):875-880. PubMed ID: 35946981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
